spacer image

View Project Russell-3U24NS043571-01S1
Project Summary
Status: Public  
Publications: 1 Published
 		 
Project Detail Data Detail
Platform: Affymetrix MIAME Areas Compliance
Species: Human Array Design Detail false
Organ/Tissue Type: blood Experiment Detail false
Organ Region: adrenal medulla Sample Detail false
Cell Type: chromaphine cells Hybridization Detail false
Study Type: pharmacogenomic Measurement Detail false
Disease/Condition: Aged, Young control
Replicates: 0
Expected Samples:  
spacer image
Available Actions
spacer image
Investigator Contact Detail
Name Paul Russell
Street Address: School of Veterinary Medicine, Unversity of Wisconsin
2015 Linden Drive
City, State/Province: Madison , WI
Zip/Postal Code: 35706
Country: United States
Work Phone: (608) 262-5652
Fax:
E-mail: russellp@svm.vetmed.wisc.edu
spacer image
Proposal Detail
Grant: 3U24NS043571-01S1
Status: Public
Service Type: Start to Finish Profiling
IRB: TBA
IRB date: 2003-09-03
Study Relevance:
Recently developed prostaglandin analogues appear to be efficacious and are well-tolerated agents for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG) and ocular hypertension. Latanoprost free acid (latanoprost) is the active form of one prostaglandin F2alpha analogue. This drug decreases IOP by increasing the aqueous outflow through the uveoscleral outflow system2,3. Compounds related to prostaglandins called prostamides are also used to reduce IOP4. These drugs, which have similar structures to prostaglandins, are thought to enhance the outflow through both the uveoscleral outflow pathway and the traditional outflow system, but the actual mechanisms of their action are still unknown. Trabecular meshwork and ciliary muscle are two major tissues of the outflow systems, but little is known about the biological changes in these two tissues with long term use of prostaglandin analogues.
Hypothesis:
This study tries to determine what longer-term changes might be happening in the ciliary muscle and trabecular meshwork cell types as opposed to the more acute changes that could occur when the compounds latanaprost and prostamide are initially added to the cells.
Specific Aim:
To discover genes that might increase aqueous humor outflow when human ciliary muscle (CM) or human trabecular meshwork (TM) cells are treated with prostaglandin F2alpha analogues, latanaprost and prostamide.
Experimental Procedure and Design:
Cultures of HCM and HTM cells were established from five different donors, treated for nine days with 10 ug/ml of either latanoprost free acid or prostaglandin F2alpha ethanolamide and compared to control cells. The mRNA from the cells of the five individual donors was pooled and will be analyzed using Affymetrix U95Av2 microarrays.
Experimental Factors:
Conditions that are tested in the experiment. At least one is required. Experimental factors are the independent variables in the experiment.
spacer image
spacer image
Experimental Factors is empty.
spacer image
Project Samples  This section lists the samples that are associated with this project. Individual sample details can be viewed by clicking on the View Sample icon to the right of the sample. If samples are selectable for analysis or for addition to a virtual
Samples associated with this project.
spacer image

Action Button Key
View Sample View Sample  
Name Description Extracts  
Ctr TM 1a trabecular meshwork 1
Ctr TM 1b Human Trabecular Meshwork 1
Latanaprost TM 1a Human Trabecular Meshwork 1
Latanaprost TM 2a Human Trabecular Meshwork 1
Prostamide TM 1a Human Trabecular Meshwork 1
Prostamide TM 2a Human Trabecular Meshwork 1
Ctr CM 1a Human Ciliary Muscle 1
Ctr CM 2a Human Ciliary Muscle 1
Latanaprost CM 1a Human Ciliary Muscle 1
Latanoprost CM 2a Human Ciliary Muscle 1
Prostamide CM 1a Human Ciliary Muscle 1
Prostamide CM 2a Human Ciliary Muscle 1
spacer image
Project Hybridizations 

Action Button Key
View Hybridization View Hybridization  
Name Array Labeled Extract Hybridization Protocol  
HG_U95Av2_13_hyb HG_U95Av2_13 Prostamide TM 2a_e1_le2
HG_U95Av2_14_hyb HG_U95Av2_14 Ctr CM 2a_e1_le2
HG_U95Av2_1_hyb HG_U95Av2_1 Ctr TM 1a_e1_le1
HG_U95Av2_2_hyb HG_U95Av2_2 Ctr TM 1b_e1_le1
HG_U95Av2_3_hyb HG_U95Av2_3 Latanaprost TM 1a_e1_le1
HG_U95Av2_4_hyb HG_U95Av2_4 Latanaprost TM 2a_e1_le1
HG_U95Av2_5_hyb HG_U95Av2_5 Prostamide TM 1a_e1_le1
HG_U95Av2_6_hyb HG_U95Av2_6 Prostamide TM 2a_e1_le1
HG_U95Av2_7_hyb HG_U95Av2_7 Ctr CM 1a_e1_le1
HG_U95Av2_8_hyb HG_U95Av2_8 Ctr CM 2a_e1_le1
HG_U95Av2_9_hyb HG_U95Av2_9 Latanaprost CM 1a_e1_le1
HG_U95Av2_10_hyb HG_U95Av2_10 Latanoprost CM 2a_e1_le1
HG_U95Av2_11_hyb HG_U95Av2_11 Prostamide CM 1a_e1_le1
HG_U95Av2_12_hyb HG_U95Av2_12 Prostamide CM 2a_e1_le1
HG_U95Av2_15_hyb HG_U95Av2_15 Ctr TM 1a_e1_le2
HG_U95Av2_16_hyb HG_U95Av2_16 Ctr TM 1b_e1_le2
HG_U95Av2_17_hyb HG_U95Av2_17 Latanaprost TM 1a_e1_le2
HG_U95Av2_18_hyb HG_U95Av2_18 Latanaprost TM 2a_e1_le2
HG_U95Av2_19_hyb HG_U95Av2_19 Prostamide TM 1a_e1_le2
HG_U95Av2_20_hyb HG_U95Av2_20 Prostamide TM 2a_e1_le3
HG_U95Av2_21_hyb HG_U95Av2_21 Prostamide TM 2a_e1_le4
HG_U95Av2_22_hyb HG_U95Av2_22 Ctr CM 1a_e1_le2
HG_U95Av2_23_hyb HG_U95Av2_23 Ctr CM 2a_e1_le3
HG_U95Av2_24_hyb HG_U95Av2_24 Ctr CM 2a_e1_le4
HG_U95Av2_25_hyb HG_U95Av2_25 Latanaprost CM 1a_e1_le2
HG_U95Av2_26_hyb HG_U95Av2_26 Latanoprost CM 2a_e1_le2
HG_U95Av2_27_hyb HG_U95Av2_27 Prostamide CM 1a_e1_le2
HG_U95Av2_28_hyb HG_U95Av2_28 Prostamide CM 2a_e1_le2
spacer image
spacer image
Project Reference Files
File Name Size
PHG-CtrCM-1aAv2-s2.CEL 10.11 Mb
PHG-CtrCM-1bAv2-s2.CEL 9.95 Mb
PHG-CtrTM-1aAv2-s2.CEL 10.07 Mb
PHG-CtrTM-1bAv2-s2.CEL 10.10 Mb
PHG-LCM-1aAv2-s2.CEL 10.12 Mb
PHG-LCM-1bAv2-s2.CEL 10.00 Mb
PHG-LTM-1aAv2-s2.CEL 10.16 Mb
PHG-LTM-1bAv2-s2.CEL 10.13 Mb
PHG-PCM-1aAv2-s2.CEL 9.92 Mb
PHG-PCM-1bAv2-s2.CEL 9.93 Mb
PHG-PTM-1aAv2-s2.CEL 9.97 Mb
PHG-PTM-1bAv2-s2.CEL 9.95 Mb
Grey dot spacer image